NASDAQ · Drug Manufacturers - Specialty & Generic

Dynavax Technologies Corporation (DVAX) Stock

$15.50 +0.00% NASDAQ: DVAX Healthcare

Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U.S.

Valuation

MetricValue
Price$15.50
Market Cap$1.82B
P/E Ratio-40.79
P/B Ratio3.40
P/S Ratio7.04
EPS (TTM)$0.20
52-Week High$15.73
52-Week Low$9.20
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-9.71%
ROA-5.33%
ROCE1.44%
Gross Margin83.67%
Operating Margin4.67%
Net Margin-19.52%
Debt/Equity0.54
Current Ratio7.62

Annual Financials (USD)

Metric20202021202220232024
Revenue$47.0M$439.0M$723.0M$232.0M$277.0M
Operating Profit$-75.0M$134.0M$284.0M$-37.0M$-4.0M
Net Profit$-75.0M$77.0M$293.0M$-6.0M$27.0M
EPS$-0.78$0.57$1.97$-0.05$0.20
Op Margin-161.6%30.6%39.2%-15.9%-1.5%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$353.0M$1.0B$986.0M$997.0M$986.0M
Total Liabilities$295.0M$817.0M$405.0M$375.0M$389.0M
Cash$32.0M$436.0M$202.0M$150.0M$96.0M
Borrowings$218.0M$257.0M$258.0M$257.0M$254.0M

Latest News

Taiwan Semiconductor Tops Q2 Targets On Leading-Edge Chip Demand Investor's Business Daily · Jul 16, 2026 B&M revenue up 2% in Q1 FY27 on growth in France Retail Insight Network · Jul 16, 2026 Goldman Sachs Adjusts PT on Bank of New York Mellon to $177 From $165, Maintains Buy Rating MT Newswires · Jul 16, 2026 Market Chatter: New York Times Moves to Void Trump Administration Subpoenas MT Newswires · Jul 16, 2026 Wells Fargo Adjusts Price Target on M&T Bank to $224 From $215, Maintains Underweight Rating MT Newswires · Jul 16, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-92.0M$336.0M$63.0M$101.0M$67.0M
Investing Cash Flow$-38.0M$5.0M$-323.0M$-158.0M$-24.0M
Financing Cash Flow$1.0M$-2.0M$1.0M$-5.0M$-109.0M
Net Cash Flow$-8.0M$404.0M$-234.0M$-52.0M$-54.0M
Free Cash Flow$-103.0M$326.0M$56.0M$96.0M$60.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.08
EV / EBITDA-51.41
FCF Yield1.70%
Quick Ratio6.94
Interest Coverage2.56
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMPH $20.22 +1.40% 12.02 $891.56M 0.00%
BBNX $15.90 +12.69% -6.53 $715.34M 0.00%
COLL $35.58 +0.54% 17.33 $1.15B 0.00%
ELVN $60.46 +0.32% -19.91 $4.32B 0.00%
EVOEvotec SE $2.01 -6.07% -3.26 $713.93M 0.00%

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U.S. and Europe, which offers protection against all identified subtypes of the hepatitis B virus. Additionally, Dynavax produces and distributes CpG 1018, the specific adjuvant ingredient used in HEPLISAV-B. Dynavax maintains several strategic alliances, including a collaboration agreement with Valneva Scotland Limited, an agreement with Serum Institute of India Pvt. Ltd., and a sublicense agreement with Merck, Sharp & Dohme Corp. The company, incorporated in 1996, was originally named Double Helix Corporation before adopting the name Dynavax Technologies Corporation in September of that year. Its corporate headquarters are situated in Emeryville, California.

Dynavax Technologies Corporation is headquartered in US.

Dynavax Technologies Corporation (DVAX) stock trades at $15.50 with a market capitalization of $1.82B. The stock is valued at a price-to-earnings (P/E) ratio of -40.79, price-to-book of 3.40, price-to-sales of 7.04. Over the past 52 weeks the stock has ranged between $9.20 and $15.73, and currently trades 1.5% below its 52-week high.

On profitability, Dynavax Technologies Corporation generates a return on equity (ROE) of -9.71%, return on capital employed of 1.44%, an operating margin of 4.67%, a net profit margin of -19.52%.

Official website: www.dynavax.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides